Skip to main content
University of California San Francisco
UCSF Health
Search UCSF
About UCSF
Search form
Search...
Twitter
About
Outreach
Vision
Neuroscience Program Bylaws
CBC
Support for Students with Disabilities
Admissions
Application Process
Other Considerations
Frequently Asked Questions
Graduate Student Fair
Curriculum
Course List
UCSF Course Catalog
Study List Filing Info
UCSF Academic Calendar
Faculty
Events
Annual Retreat
Formal Seminar Series
External Postdoc Seminar Program (EPSP)
Neuroscience Program and Community Calendar
RIPS
Kavli Faculty Seminar
Contact
Program Resources
You are here
Home
>
Lancet (London, England)
Lancet (London, England)
Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial.
Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial.
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.
Interferons in relapsing remitting multiple sclerosis.
Interferons in relapsing remitting multiple sclerosis.
Autoimmune (idiopathic) thrombocytopenic purpura.
Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes.
Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes.
Neurogenic mechanism for symmetrical arthritis.
Pages
1
2
next ›
last »
